| scholarly article | Q13442814 |
| P50 | author | Til Wykes | Q7802018 |
| Trevor W. Robbins | Q7839400 | ||
| Michael Foster Green | Q80152612 | ||
| John Krystal | Q104111313 | ||
| Robert W. Buchanan | Q109937282 | ||
| Milton Strauss | Q125344949 | ||
| Robert Heinssen | Q125344958 | ||
| Deanna M. Barch | Q24580798 | ||
| P2093 | author name string | Jonathan D Cohen | |
| Cameron S Carter | |||
| Mark Geyer | |||
| Steven Silverstein | |||
| Edward E Smith | |||
| Amy Arnsten | |||
| Keith Nuechterlein | |||
| P2860 | cites work | Implications of clinical trial design on sample size requirements | Q37076415 |
| Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change | Q37158867 | ||
| Building a clinically relevant cognitive task: case study of the AX paradigm | Q37166922 | ||
| Implementation considerations for multisite clinical trials with cognitive neuroscience tasks | Q37170027 | ||
| The neurobiology of cognition in schizophrenia. | Q48380325 | ||
| Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. | Q51935852 | ||
| Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia | Q34327777 | ||
| Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders | Q35810041 | ||
| Adrenergic targets for the treatment of cognitive deficits in schizophrenia | Q35810047 | ||
| Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia | Q35810054 | ||
| Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists | Q35810060 | ||
| Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction | Q35810087 | ||
| Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria | Q35874170 | ||
| Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative | Q36881172 | ||
| Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative | Q36961097 | ||
| The translation of cognitive paradigms for patient research | Q37029355 | ||
| Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative | Q37076386 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cognitive neuroscience | Q1138951 |
| neuroscience | Q207011 | ||
| P304 | page(s) | 109-114 | |
| P577 | publication date | 2008-11-20 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting | |
| P478 | volume | 35 |
| Q26768572 | A Metaanalysis of Perceptual Organization in Schizophrenia, Schizotypy, and Other High-Risk Groups Based on Variants of the Embedded Figures Task |
| Q48271960 | A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. |
| Q37309730 | Altered contextual modulation of primary visual cortex responses in schizophrenia |
| Q38139257 | Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives |
| Q37960443 | CNTRICS imaging biomarker selections: Executive control paradigms |
| Q35632474 | Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium |
| Q34109138 | Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different |
| Q33884990 | Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders |
| Q35555297 | Cognitive abilities on transitive inference using a novel touchscreen technology for mice |
| Q38181123 | Cognitive remediation in schizophrenia: current status and future perspectives |
| Q58583400 | Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes |
| Q30396775 | Developing treatments for cognitive deficits in schizophrenia: the challenge of translation |
| Q37437840 | Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment |
| Q37279397 | Dopaminergic control of cognitive flexibility in humans and animals |
| Q50749475 | Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. |
| Q24630385 | Evaluation of the clinical efficacy of asenapine in schizophrenia |
| Q35914629 | Examining the genetic and neural components of cognitive flexibility using mice |
| Q30997126 | Exome Sequence Data From Multigenerational Families Implicate AMPA Receptor Trafficking in Neurocognitive Impairment and Schizophrenia Risk |
| Q34218300 | Functional neuroimaging of treatment effects in psychiatry: methodological challenges and recommendations |
| Q37624462 | Future classification of psychotic disorders |
| Q27014120 | Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia |
| Q41717521 | Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients |
| Q37662401 | Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models |
| Q35632516 | Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development |
| Q35898783 | Impaired associative inference in patients with schizophrenia |
| Q47891942 | Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits |
| Q37820663 | Modular networks involving the medial frontal cortex: towards the development of neuropsychiatry |
| Q48559497 | Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study |
| Q30457807 | Mouse pharmacological models of cognitive disruption relevant to schizophrenia |
| Q47932815 | Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat. |
| Q46116077 | Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle |
| Q46723526 | Opposing effects of glutamatergic and GABAergic pharmacological manipulations on a visual perception task with relevance to schizophrenia. |
| Q35632478 | Optimization and validation of a visual integration test for schizophrenia research |
| Q35632494 | Optimization of a goal maintenance task for use in clinical applications |
| Q43626490 | Perceptual organization and visual search processes during target detection task performance in schizophrenia, as revealed by fMRI |
| Q46038979 | Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. |
| Q36852166 | Psychobiological operationalization of RDoC constructs: Methodological and conceptual opportunities and challenges |
| Q38187948 | Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets |
| Q47583197 | Reciprocal causation models of cognitive vs volumetric cerebral intermediate phenotypes for schizophrenia in a pan-European twin cohort |
| Q44193437 | Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients |
| Q48131925 | Relationships among medication adherence, insight, and neurocognition in chronic schizophrenia |
| Q27311539 | Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale |
| Q30446313 | Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice |
| Q35760205 | Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator |
| Q37342350 | Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation |
| Q35231692 | Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP). |
| Q33762481 | Temporal stability and moderating effects of age and sex on CNTRaCS task performance |
| Q47885564 | The NIMH Research Domain Criteria Initiative: Background, Issues, and Pragmatics |
| Q43549835 | The combined effects of the 5- HTTLPR and HTR1A rs6295 polymorphisms modulate decision making in schizophrenia patients |
| Q35679951 | The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder |
| Q38025454 | The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence |
| Q30450648 | Turning it upside down: areas of preserved cognitive function in schizophrenia |
| Q30540282 | Using standardized fMRI protocols to identify patterns of prefrontal circuit dysregulation that are common and specific to cognitive and emotional tasks in major depressive disorder: first wave results from the iSPOT-D study |
| Q30489404 | Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia |
| Q82261891 | [Neuroimaging markers: their role for differential diagnosis and therapeutic decisions in personalized psychiatry] |
| Q37465460 | nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. |
Search more.